Combination of Platelets Rich Plasma and Hyaluronic is an Effective Tool for Treatment of Knee Osteoarthritis

NCT07089446 | Completed DMC

• 1 other identifier: SCH-IRB-2022-05
• Study Type: interventional
• Target: 60
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of the study is to determine the effects of HA, PRP and the combination of HA and PRP in reducing pain and improving functional disability in patients with knee osteoarthritis.

Conditions

Knee Osteoarthristis

Keywords

Hyaluronic acid; osteoarthritis; pain; disability

Outcome Measures

Primary Outcomes (1)

• visual analogue scale

  It is a straight line, 100 millimeters long line, one end of the line means "not at all" or "none" and the other end means "the worst possible" or "extremely".

  Recorded before the treatment and repeated within 3 and 6 months after the treatment.

Secondary Outcomes (1)

• Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)

  Recorded before the treatment and repeated within 3 and 6 months after the treatment.

Study Arms (3)

Group A

EXPERIMENTAL

Hyaluronic acid

Drug: Hyaluronic Acid (HA)

Group B

ACTIVE COMPARATOR

platelet rich plasma

Drug: Platelet Rich Plasma

Group C

OTHER

Hyaluronic acid and platelet rich plasma

Drug: Hyaluronic Acid (HA) and Platelet rich plasma

Interventions

Hyaluronic Acid (HA) DRUG

Hyaluronic Acid

Group A

Platelet Rich Plasma DRUG

Platelet rich plasma

Group B

Hyaluronic Acid (HA) and Platelet rich plasma DRUG

Hyaluronic Acid and Platelet rich plasma

Group C

Eligibility Criteria

• Age: 40 Years - 70 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• grade II-III according to the Kellgren-Lawrence classification),
• pain or functional limitations in patients' activity of daily living before the treatment,
• age between 40 and 70 years of age, and the absence of clinical or imaging signs of articular instability.

You may not qualify if:

• includes known hypersensitivity to hyaluronic acid,
• pregnancy and lactation, a BMI greater than 40 kg/m2,
• chronic administration of anticoagulant drugs or a history of coagulopathies,
• neoplastic lesions, and knee or kidney failures

Sponsors & Collaborators

• University of Karachi: lead

Study Sites (1)

South City Hospital

Karachi, Sindh, 75600, Pakistan

Location

MeSH Terms

Conditions

Osteoarthritis; Pain

Interventions

Hyaluronic Acid

Condition Hierarchy (Ancestors)

Arthritis; Joint Diseases; Musculoskeletal Diseases; Rheumatic Diseases; Neurologic Manifestations; Signs and Symptoms; Pathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Glycosaminoglycans; Polysaccharides; Carbohydrates

Study Officials

• Basit Ansari, PhD

  University of Karachi

  STUDY CHAIR

• Ranjeet Kumar, MBBS, FCPS

  University of Karachi

  PRINCIPAL INVESTIGATOR

• Aftab Ahmed Mirza Baig, PhD

  IQRA University

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: SINGLE
• Who Masked: OUTCOMES ASSESSOR
• Masking Details: Single blinded study, only the assessor was kept blinded
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal investigator

Model Details: Participants were randomly divided into three groups. Twenty cases (Group A) were injected with HA, 20 (Group B) had PRP, and the remaining 20 (Group C) received a combination of HA and PRP

Study Record Dates

• First Submitted: July 20, 2025
• First Posted: July 28, 2025
• Study Start: September 21, 2022
• Primary Completion: May 2, 2025
• Study Completion: June 15, 2025
• Last Updated: July 28, 2025

Record last verified: 2025-07

Locations

PA (1)